BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31993940)

  • 1. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
    Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
    Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What did we learn from CTLA-4 insufficiency on the human immune system?
    Mitsuiki N; Schwab C; Grimbacher B
    Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preponderance of
    Siggs OM; Russell A; Singh-Grewal D; Wong M; Chan P; Craig ME; O'Loughlin T; Stormon M; Goodnow CC
    Front Immunol; 2019; 10():1544. PubMed ID: 31396201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.
    Schwab C; Gabrysch A; Olbrich P; Patiño V; Warnatz K; Wolff D; Hoshino A; Kobayashi M; Imai K; Takagi M; Dybedal I; Haddock JA; Sansom DM; Lucena JM; Seidl M; Schmitt-Graeff A; Reiser V; Emmerich F; Frede N; Bulashevska A; Salzer U; Schubert D; Hayakawa S; Okada S; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Sumnik Z; Sediva A; Slatter M; Arkwright PD; Cant A; Lorenz HM; Giese T; Lougaris V; Plebani A; Price C; Sullivan KE; Moutschen M; Litzman J; Freiberger T; van de Veerdonk FL; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Speckmann C; Ehl S; Leichtner A; Blumberg R; Franke A; Snapper S; Zeissig S; Cunningham-Rundles C; Giulino-Roth L; Elemento O; Dückers G; Niehues T; Fronkova E; Kanderová V; Platt CD; Chou J; Chatila TA; Geha R; McDermott E; Bunn S; Kurzai M; Schulz A; Alsina L; Casals F; Deyà-Martinez A; Hambleton S; Kanegane H; Taskén K; Neth O; Grimbacher B
    J Allergy Clin Immunol; 2018 Dec; 142(6):1932-1946. PubMed ID: 29729943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report.
    Mazzoni M; Dell'Orso G; Grossi A; Ceccherini I; Viola S; Terranova P; Micalizzi C; Guardo D; Massaccesi E; Palmisani E; Calvillo M; Fioredda F; Malattia C; Dufour C; Ravelli A; Miano M
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1168-e1172. PubMed ID: 33625086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
    Schubert D; Bode C; Kenefeck R; Hou TZ; Wing JB; Kennedy A; Bulashevska A; Petersen BS; Schäffer AA; Grüning BA; Unger S; Frede N; Baumann U; Witte T; Schmidt RE; Dueckers G; Niehues T; Seneviratne S; Kanariou M; Speckmann C; Ehl S; Rensing-Ehl A; Warnatz K; Rakhmanov M; Thimme R; Hasselblatt P; Emmerich F; Cathomen T; Backofen R; Fisch P; Seidl M; May A; Schmitt-Graeff A; Ikemizu S; Salzer U; Franke A; Sakaguchi S; Walker LSK; Sansom DM; Grimbacher B
    Nat Med; 2014 Dec; 20(12):1410-1416. PubMed ID: 25329329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
    Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
    Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual Late-onset Enteropathy in a Patient With Lipopolysaccharide-responsive Beige-like Anchor Protein Deficiency.
    Maggiore R; Grossi A; Fioredda F; Palmisani E; Terranova P; Cappelli E; Lanza T; Pierri F; Guardo D; Calvillo M; Micalizzi C; Beccaria A; Coccia MC; Arrigo S; Dufour C; Ceccherini I; Miano M
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e768-e771. PubMed ID: 31876783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
    Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
    Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for CTLA-4 insufficiency.
    Egg D; Rump IC; Mitsuiki N; Rojas-Restrepo J; Maccari ME; Schwab C; Gabrysch A; Warnatz K; Goldacker S; Patiño V; Wolff D; Okada S; Hayakawa S; Shikama Y; Kanda K; Imai K; Sotomatsu M; Kuwashima M; Kamiya T; Morio T; Matsumoto K; Mori T; Yoshimoto Y; Dybedal I; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Lorenz HM; Sullivan KE; Heimall J; Moutschen M; Litzman J; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Snapper S; Giulino-Roth L; Svaton M; Platt CD; Hambleton S; Neth O; Gosse G; Reinsch S; Holzinger D; Kim YJ; Bakhtiar S; Atschekzei F; Schmidt R; Sogkas G; Chandrakasan S; Rae W; Derfalvi B; Marquart HV; Ozen A; Kiykim A; Karakoc-Aydiner E; Králíčková P; de Bree G; Kiritsi D; Seidel MG; Kobbe R; Dantzer J; Alsina L; Armangue T; Lougaris V; Agyeman P; Nyström S; Buchbinder D; Arkwright PD; Grimbacher B
    J Allergy Clin Immunol; 2022 Feb; 149(2):736-746. PubMed ID: 34111452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
    Kuehn HS; Ouyang W; Lo B; Deenick EK; Niemela JE; Avery DT; Schickel JN; Tran DQ; Stoddard J; Zhang Y; Frucht DM; Dumitriu B; Scheinberg P; Folio LR; Frein CA; Price S; Koh C; Heller T; Seroogy CM; Huttenlocher A; Rao VK; Su HC; Kleiner D; Notarangelo LD; Rampertaap Y; Olivier KN; McElwee J; Hughes J; Pittaluga S; Oliveira JB; Meffre E; Fleisher TA; Holland SM; Lenardo MJ; Tangye SG; Uzel G
    Science; 2014 Sep; 345(6204):1623-1627. PubMed ID: 25213377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency.
    Taghizade N; Babayeva R; Kara A; Karakus IS; Catak MC; Bulutoglu A; Haskologlu ZS; Akay Haci I; Tunakan Dalgic C; Karabiber E; Bilgic Eltan S; Yorgun Altunbas M; Sefer AP; Sezer A; Kokcu Karadag SI; Arik E; Karali Z; Ozhan Kont A; Tuzer C; Karaman S; Mersin SS; Kasap N; Celik E; Kocacik Uygun DF; Aydemir S; Kiykim A; Aydogmus C; Ozek Yucel E; Celmeli F; Karatay E; Bozkurtlar E; Demir S; Metin A; Karaca NE; Kutukculer N; Aksu G; Guner SN; Keles S; Reisli I; Kendir Demirkol Y; Arikoglu T; Gulez N; Genel F; Kilic SS; Aytekin C; Keskin O; Yildiran A; Ozcan D; Altintas DU; Ardeniz FO; Dogu EF; Ikinciogullari KA; Karakoc-Aydiner E; Ozen A; Baris S
    J Allergy Clin Immunol; 2023 Dec; 152(6):1634-1645. PubMed ID: 37595759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
    Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
    Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Phenotypes and Immunological Characteristics of 18 Egyptian LRBA Deficiency Patients.
    Meshaal S; El Hawary R; Adel R; Abd Elaziz D; Erfan A; Lotfy S; Hafez M; Hassan M; Johnson M; Rojas-Restrepo J; Gamez-Diaz L; Grimbacher B; Shoman W; Abdelmeguid Y; Boutros J; Galal N; El-Guindy N; Elmarsafy A
    J Clin Immunol; 2020 Aug; 40(6):820-832. PubMed ID: 32506362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifocal gastric adenocarcinoma in a patient with LRBA deficiency.
    Bratanič N; Kovač J; Pohar K; Trebušak Podkrajšek K; Ihan A; Battelino T; Avbelj Stefanija M
    Orphanet J Rare Dis; 2017 Jul; 12(1):131. PubMed ID: 28720148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygous
    Mahat U; Ambani NM; Rotz SJ; Radhakrishnan K
    Pediatr Hematol Oncol; 2021 Oct; 38(7):658-662. PubMed ID: 33900894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.
    Zaremehrjardi F; Baniadam L; Seif F; Arshi S; Bemanian MH; Shokri S; Rezaeifar A; Fallahpour M; Nabavi M
    Iran J Immunol; 2020 Sep; 17(3):244-249. PubMed ID: 32996901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
    Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
    Front Immunol; 2019; 10():998. PubMed ID: 31156616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer.
    Hayakawa S; Okada S; Tsumura M; Sakata S; Ueno Y; Imai K; Morio T; Ohara O; Chayama K; Kobayashi M
    J Clin Immunol; 2016 Jan; 36(1):28-32. PubMed ID: 26644313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and molecular mechanisms of immune dysregulation and autoimmunity.
    Azizi G; Pouyani MR; Abolhassani H; Sharifi L; Dizaji MZ; Mohammadi J; Mirshafiey A; Aghamohammadi A
    Cell Immunol; 2016 Dec; 310():14-26. PubMed ID: 27614846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.